» Articles » PMID: 32866159

Prediction of Immunogenicity for Humanized and Full Human Therapeutic Antibodies

Overview
Journal PLoS One
Date 2020 Sep 1
PMID 32866159
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Immunogenicity is an important concern for therapeutic antibodies during drug development. By analyzing co-crystal structures of idiotypic antibodies and their antibodies, we found that anti-idiotypic antibodies usually bind the Complementarity Determining Regions (CDR) of idiotypic antibodies. Sequence and structural features were identified for distinguishing immunogenic antibodies from non-immunogenic antibodies. For example, non-immunogenic antibodies have a significantly larger cavity volume at the CDR region and a more hydrophobic CDR-H3 loop than immunogenic antibodies. Antibodies containing no Gly at the turn of CDR-H2 loop are often immunogenic. We integrated these features together with a machine learning platform to Predict Immunogenicity for humanized and full human THerapeutic Antibodies (PITHA). This method achieved an accuracy of 83% in leave-one-out experiment for 29 therapeutic antibodies with available crystal structures. The accuracy decreased to 65% for 23 test antibodies with modeled structures, because their crystal structures were not available, and the prediction was made with modeled structures. The server of this method is accessible at http://mabmedicine.com/PITHA.

Citing Articles

Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present.

Naman J, Shah N, Heyman B Int J Mol Sci. 2025; 26(4).

PMID: 40004173 PMC: 11855020. DOI: 10.3390/ijms26041711.


Plasticity of BioPhi-driven humanness optimization in ScFv-CD99 binding affinity validated through AlphaFold, HADDOCK, and MD simulations.

Sornsuwan K, Pamonsupornwichit T, Juntit O, Thongkum W, Takheaw N, Kodchakorn K Comput Struct Biotechnol J. 2025; 27:369-382.

PMID: 39897056 PMC: 11786912. DOI: 10.1016/j.csbj.2025.01.001.


Exploring the Biological Activity of a Humanized Anti-CD99 ScFv and Antibody for Targeting T Cell Malignancies.

Takheaw N, Pamonsupornwichit T, Chaiwut R, Kotemul K, Sornsuwan K, Juntit O Biomolecules. 2024; 14(11).

PMID: 39595598 PMC: 11592157. DOI: 10.3390/biom14111422.


AbImmPred: An immunogenicity prediction method for therapeutic antibodies using AntiBERTy-based sequence features.

Wang H, Hao X, He Y, Fan L PLoS One. 2024; 19(2):e0296737.

PMID: 38394128 PMC: 10889861. DOI: 10.1371/journal.pone.0296737.


Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics.

Licari G, Martin K, Crames M, Mozdzierz J, Marlow M, Karow-Zwick A Mol Pharm. 2022; 20(2):1096-1111.

PMID: 36573887 PMC: 9906779. DOI: 10.1021/acs.molpharmaceut.2c00838.


References
1.
Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M . Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010; 11:568. PMC: 2998531. DOI: 10.1186/1471-2105-11-568. View

2.
Ito S, Ikuno T, Mishima M, Yano M, Hara T, Kuramochi T . human helper T-cell assay to screen antibody drug candidates for immunogenicity. J Immunotoxicol. 2019; 16(1):125-132. DOI: 10.1080/1547691X.2019.1604586. View

3.
Kulkarni-Kale U, Bhosle S, Kolaskar A . CEP: a conformational epitope prediction server. Nucleic Acids Res. 2005; 33(Web Server issue):W168-71. PMC: 1160221. DOI: 10.1093/nar/gki460. View

4.
Mazor R, Crown D, Addissie S, Jang Y, Kaplan G, Pastan I . Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. Cell Mol Immunol. 2015; 14(5):432-442. PMC: 5423085. DOI: 10.1038/cmi.2015.91. View

5.
Sweredoski M, Baldi P . PEPITO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure. Bioinformatics. 2008; 24(12):1459-60. DOI: 10.1093/bioinformatics/btn199. View